QBiotics announces clinical collaboration with MSD targeting unresectable melanoma
QBiotics Group Limited (QGL), a life sciences company developing novel anticancer and wound healing pharmaceuticals,…
Browsing: pembrolizumab
Use of pembrolizumab provided long-term benefits in patients with metastatic melanoma, 10-year look shows
A new 10-year analysis led by Igor Puzanov, MD, MSci, FACP, Director of Early Phase…
EHA 2020: A new treatment paradigm in relapsed refractory Hodgkin lymphoma
Patients with relapsed/refractory classical Hodgkin lymphoma (R/R cHL) have few treatment options when they are…
ASCO 2020: Researchers underscore efficacy of pembrolizumab plus axitinib in treating advanced renal cell carcinoma
Researchers at Fox Chase Cancer Center, USA, along with an international team of investigators, have…
ASCO 2020: Pembrolizumab doubles time to disease progression in patients with advanced colorectal cancer with specific DNA mutations
Front-line therapy with the immune checkpoint inhibitor pembrolizumab doubled progression-free survival vs chemotherapy in patients…
ASCO 2020: Pembrolizumab plus chemotherapy demonstrated improvement in PFS for patients with metastatic triple-negative breast cancer
Merck has announced positive results from the Phase 3 KEYNOTE-355 trial investigating pembrolizumab in combination with…
Novel biomarkers predict benefit with immunotherapy in metastatic breast cancer
Two novel biomarkers have been found to correlate with improved outcomes with immunotherapy in metastatic…
Pembrolizumab shows promise for some advanced, hard-to-treat rare cancers
A study conducted by researchers at The University of Texas MD Anderson Cancer Center, USA,…
Immune therapy reduces risk of recurrence in aggressive breast cancer
An immune therapy for the most aggressive form of breast cancer can substantially reduce the…
Study shows long-term survival benefit for certain patients with advanced lung cancer
According to the results of a large, global study led by Yale Cancer Center, USA,…